J&J unit enrolls first patient in SMART-AF study

Biosense Webster, a unit of Johnson & Johnson, has reported the enrollment of the first patient in the SMART-AF IDE study, as well as the treatment of the first patient with the new Thermocool Smarttouch contact force sensing catheter and software module in the U.S. SMART-AF expects to enroll up to 164 patients across the country. The study is trying to demonstrate the safety and effectiveness of the Thermocool Smarttouch in the treatment of symptomatic, drug-refractory, paroxysmal atrial fibrillation Biosense Webster release

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.